Toronto Dominion Bank Increases Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Toronto Dominion Bank boosted its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 18.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 153,690 shares of the company's stock after purchasing an additional 24,293 shares during the period. Toronto Dominion Bank's holdings in GE HealthCare Technologies were worth $14,424,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GEHC. State Street Corp raised its holdings in GE HealthCare Technologies by 7.8% in the 3rd quarter. State Street Corp now owns 18,615,890 shares of the company's stock worth $1,747,101,000 after purchasing an additional 1,347,114 shares during the period. Geode Capital Management LLC raised its stake in shares of GE HealthCare Technologies by 7.2% in the third quarter. Geode Capital Management LLC now owns 10,977,757 shares of the company's stock worth $1,026,898,000 after buying an additional 733,819 shares during the period. D1 Capital Partners L.P. bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at approximately $268,159,000. Charles Schwab Investment Management Inc. increased its holdings in GE HealthCare Technologies by 12.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,710,938 shares of the company's stock worth $254,422,000 after acquiring an additional 290,019 shares in the last quarter. Finally, Van ECK Associates Corp bought a new stake in GE HealthCare Technologies during the 3rd quarter worth approximately $208,513,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GEHC. BTIG Research raised shares of GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Wednesday, September 18th. UBS Group lowered GE HealthCare Technologies from a "neutral" rating to a "sell" rating and cut their price target for the stock from $84.00 to $74.00 in a research note on Thursday, September 26th. Stifel Nicolaus boosted their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Wells Fargo & Company upped their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a research note on Thursday, October 31st. Finally, Evercore ISI lifted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $95.46.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Trading Down 0.6 %

Shares of NASDAQ GEHC traded down $0.53 during trading hours on Friday, hitting $81.10. 2,836,005 shares of the company traded hands, compared to its average volume of 3,052,807. The company's 50 day moving average price is $85.84 and its 200 day moving average price is $83.74. GE HealthCare Technologies Inc. has a 12 month low of $71.31 and a 12 month high of $94.55. The stock has a market capitalization of $37.05 billion, a price-to-earnings ratio of 22.28, a price-to-earnings-growth ratio of 2.96 and a beta of 1.07. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The business had revenue of $4.86 billion for the quarter, compared to analysts' expectations of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business's revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.99 earnings per share. On average, equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be paid a $0.035 dividend. The ex-dividend date is Tuesday, January 14th. This represents a $0.14 annualized dividend and a yield of 0.17%. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. GE HealthCare Technologies's dividend payout ratio (DPR) is presently 3.85%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.